XML 18 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Operating Activities    
Net loss $ (92,472) $ (39,291)
Adjustments to reconcile net loss to cash used in operating activities:    
Depreciation, amortization and accretion 8,005 5,878
Impairment expense 64,649 4,286
Stock-based compensation expense 4,018 2,485
(Gain) loss from contingent considerations (761) 2,680
Amortization of senior debt (premium) discount (268) 115
(Gain) loss on sale of equipment (44) 112
Gain on termination of lease   (343)
(Gain) loss on debt extinguishment (193) 258
Inventory write-down 352 7,227
Gain on derivative warrant liability (211)  
Other noncash adjustments (152) 335
Changes in operating assets and liabilities:    
Accounts receivable 647 1,764
Inventory 91 (4,390)
Prepaid expenses and other current assets 1,406 7,673
Accounts payable and other (8,099) (6,156)
Accrued liabilities 1,252 (2,293)
Other operating assets and liabilities, net 52 (27)
Net cash used in operating activities (21,728) (19,687)
Investing Activities    
Contingent consideration payment (3,138) (683)
Cash received from acquisition   15,722
Cash payment for business acquisition   (15,399)
Other investing activities (69) 4
Net cash used in investing activities (3,207) (356)
Financing Activities    
Proceeds from issuance of stock 12,700 32,250
Payment of stock issuance costs (782) (4,430)
Payment made to fixed payment arrangement (3,277) (3,034)
Proceeds from short-term line of credit 112,463  
Payments made on short-term line of credit (117,012) (5,968)
Payments made to borrowings (16,075) (318)
Proceeds from borrowings 15,000  
Payment for debt issuance costs (363)  
Other financing activities (7)  
Net cash provided by financing activities 2,647 18,500
Net change in cash, restricted cash and cash equivalents (22,288) (1,543)
Cash, cash equivalents and restricted cash at beginning of period 49,901 48,333
Cash, cash equivalents and restricted cash at end of period 27,613 46,790
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets    
Cash and cash equivalents 27,613 46,538
Restricted cash   252
Total cash, cash equivalents and restricted cash 27,613 46,790
Supplemental cash flow data    
Cash paid for interest 3,080 449
Non-cash investing and financing activities:    
Warrants issued 3,177 1,628
Other noncash investing and financing activities $ 473 66
Fixed payment arrangements included in accrued liabilities   1,575
Issuance of common stock for note conversion   1,058
Contingent value rights payout   1,000
Issuance related to acquisition of Neos   53,241
Fair value of non-cash assets acquired   104,322
Fair value of liabilities assumed   88,700
Estimated fair value of replacement equity awards   $ 432